AMBU B Ambu A/S Class B

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees. 

The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT margin) for the fiscal year 2023/24 and will be within the range of 0-200% of the initial grant. 

The PSUs are granted free and subject to achievement of the KPIs mentioned above. Each PSU will at vesting, on 1 January 2027, be converted to one Class B share in Ambu A/S subject to the terms of the LTIP. 

The average price applied to calculate the number of PSUs is the average price quoted by NASDAQ Copenhagen in respect of Ambu A/S Class B shares on the day of the Annual General Meeting and the subsequent four (4) trading days (13-19 December 2023). 

The value of the PSUs will, at the time of vesting, be capped at four times the annual base salary of the individual participant measured at the time of the grant. 





Ambu A/S

Baltorpbakken 13 2750 Ballerup 

Denmark

Tel.  

CVR no.: 63 64 49 19





CONTACT

Investors 

Anders Hjort 

Head of Investor Relations

 





Media 

Tine Bjørn Schmidt

Head of Corporate Communications







ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit .

Attachment



EN
06/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 12,500 shares at 118.560DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Ambu A/S: Reporting of transactions made by persons discharging manage...

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.   The attached document discloses the data of the transactions made in Ambu shares.  Attachment

 PRESS RELEASE

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.  The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT marg...

Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK130.00) - Strong Q1 suggests promising 2024

With a c20% EBIT beat driven by the top line and profitability, Q1 showed Ambu is off to a strong start to 2023/24. However, the guidance was maintained and remains conservative in our view, while recent price rises to the legacy business and more reimbursement for the aScope 5 leave further upside potential. We reiterate our BUY and have raised our target price to DKK130 (120).

 PRESS RELEASE

INTERIM REPORT FOR Q1 2023/24

INTERIM REPORT FOR Q1 2023/24 In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive free cash flow of DKK 135m, we are off to a solid start ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch